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SirT3Berberine is an isoquinoline alkaloid with anti-diabetic properties. Despite the central role of liver and thus
hepaticmitochondria in whole-bodymetabolism, berberine effects on hepatic mitochondrial function in an obe-
sity model are still unknown. Here, we demonstrate that berberine treatment recovers mitochondrial efficiency
when altered by a high-fat feeding. Mitochondria isolated from the liver of high-fat fed rats exhibited decreased
capacity to accumulate calcium and impaired oxidative phosphorylation (OXPHOS) capacity, as shown by
impaired mitochondrial membrane potential, oxygen consumption and cellular ATP levels. Interestingly, the re-
covery of mitochondrial function by berberine was associated with an increased activity of the mitochondrial
sirtuin 3 (SirT3). In conclusion, berberine potent protective effects against metabolic syndrome may rely on
increasing mitochondrial SirT3 activity, normalizing mitochondrial function and preventing a state of energetic
deficit caused by impaired OXPHOS.
© 2013 Elsevier B.V. and Mitochondria Research Society. All rights reserved.1. Introduction
Metabolic syndrome, a pre-diabetic condition, is considered a global
epidemic due to the elevated incidence of obesity promoted by the
western lifestyle and high fat dietary intake (Haslam and James,
2005). This pathological state is a multifactorial conditionwith elevated
morbidity due to the combination of various characteristics, such as
abdominal obesity, hyperglycemia, dyslipidemia, insulin resistance, ele-
vated risk of cardiac complications and even cancer (Haslam and James,
2005). This can lead to anomalies in glucose and lipid metabolism
throughout the organism, with particular relevance in the liver, muscle
and adipocytes (Carley and Severson, 2005). Since the liver occupies a
central role in whole-body metabolic regulation, the imbalance of
hepatic function by increased availability of nutrients is known to lead
to several complications. Intrahepatocytical lipid accumulation has
been linked to hepatic and peripheral insulin resistance in type II diabe-
tes (T2D) patients, impaired pancreatic β-cell function and hepaticAMP-activated protein kinase;
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Mitochondria Research Society. All rigsteatosis (Shah et al., 2003). Steatosis is the basis for the induction of
liver cirrhosis and inflammatory steatohepatitis (Clark and Diehl,
2003) and can occur in parallel to obesity and/or T2D (Haque and
Sanyal, 2002). The hepatic increase in free fatty acids (FFA) leads to mi-
tochondrial dysfunction, ATP depletion and also increased generation of
reactive oxygen species (ROS) (Pessayre, 2007).
In the eukaryotic cell, mitochondria are themain ATP generation site.
As such, it is of no surprise that altered mitochondrial metabolism is a
common hallmark of several pathologies. The excessive FFA accumula-
tion in hepatocytes causes the impairment of mitochondrial bioenerget-
ics that parallels the metabolic evolution of fatty liver disease (Teodoro
et al., 2006, 2008). Due to mitochondrial oxidative phosphorylation
activity, mitochondria are the prime site of intracellular ROS generation.
As such, an imbalance of the cell's redox environment will most likely
originate in and affect the cell's mitochondria, despite its natural antiox-
idant defenses. In fact, it has been reported that, in T2D patients, there is
a higher number of damaged mitochondria with reduced mitochondrial
volume (Kelley et al., 2002). Concomitantly, this leads to a vicious
cycle due to the fact that excessive ROS generation leads to membrane
lipid and respiratory chain protein alterations, decreasing the electronic
transport capacity and thus increasing ROS generation (Pessayre et al.,
2001).
The alterations of the function and activity of these metabolically
relevant proteins can happen by several means. One way to achieve
metabolic regulation by protein function alteration is the regulation of
the acetylation. Sirtuin 3 (SirT3) is localized within the mitochondrialhts reserved.
638 J.S. Teodoro et al. / Mitochondrion 13 (2013) 637–646matrix,where it controls acetylation levels of enzymes involved in ener-
gy metabolism processes, including the respiratory chain, Krebs cycle
and mitochondrial fatty acid β-oxidation. High-fat diets have been
shown to reduce SirT3 activity, causing hyperacetylation of a diverse
set of liver proteins, contributing to reduced efficiency of themitochon-
drial oxidative phosphorylation (OXPHOS) and potentiating lipotoxicity
under conditions of nutrient excess (Choudhury et al., 2011; Hirschey
et al., 2010; Kendrick et al., 2011).
Berberine (BBR) is an isoquinoline alkaloid present in several plants
used in traditional Chinese medicine, which is known to reduce blood
glucose levels in T2D (Yin et al., 2008). As such, it is considered as a
natural product with hypoglycemic action and a potent reducer of
bodyweight in obese animals. The action of this compound is associated
with a decreased expression of genes involved in lipogenesis, and an in-
creased activity of AMP-activated protein kinase (AMPK) and expression
of genes involved in energy expenditure (Gomes et al., 2012; Lee et al.,
2006; Zhou et al., 2008). Previous studies demonstrated that BBR might
improve insulin sensitivity through amechanism related to the deactiva-
tion of acetyl-CoA carboxylase (ACC) and, thus, increase the rate of fatty
acid oxidation (Kong et al., 2009; Lee et al., 2006; Zhang et al., 2009).
It was also reported that BBR, in the liver of diabetic rats, decreased
fasting glucose, hepatic steatosis and the expression of several
gluconeogenic genes such as Phosphoenolpyruvate Carboxykinase
(PEPCK) and Glucose-6-Phosphatase (G6Pase) (Xia et al., 2011).
To this day, to the best of our knowledge, no study has fully charac-
terized hepatic mitochondrial function when exposed to BBR. In this
study, we evaluated the effects of BBR on the mitochondrial function
of steatotic livers and how this protects the liver against the conditions
associated with the incidence of obesity.
2. Experimental procedures
2.1. Animals, diets and treatments
Male Sprague–Dawley rats aged 6–8 weekswere housed under con-
trolled light and humidity conditions and given ad libitum access to
water and standard chow (control group) or an isocaloric high fat diet
(HFD) for 12 weeks. After 12 weeks, the HFD group was divided into
two groups: one was kept in the same conditions and a third group
was maintained on HFD with a supplement of BBR (100 mg/kg/day)
in the drinking water for 4 more weeks (BBR). After these 16 weeks of
study, animals were sacrificed, in the fed state, by cervical dislocation,
in the early hours of the morning.
BBR and food intake were monitored over the study to insure that
each animal consumed roughly the same amount of BBR and calories
(by water volume consumption and food weight in cage). The diets
were purchased from Research Diets, Inc (New Jersey, USA). The diet
used to induce obesity (HFD) has 60% of its calorie count derived from
fat, whereas the control diet (Ctl) has 10% calories derived from fat. All
experimental procedures respected the guidelines of the European Di-
rective 10386/609/CEE, the Declaration of Helsinki and those present
in the Portuguese law.
2.2. Materials
Except when noted, all compounds were purchased from Sigma
Chemical Co. (St. Louis, MO). All reagents and chemicals used were of
the highest grade of purity commercially available.
2.3. Plasma biochemical determination
Plasma samples were immediately collected after animal sacrifice
and enzymatic determinations were performed using commercial kits.
Plasma glucose was determined by a glucometer (Accu-chek Aviva —
Roche, Portugal). Plasma insulin levels were determined by ELISA
(EZRMI-13K — Millipore, Portugal). Plasma leptin and adiponectinlevels were measured using a commercially available kit (Invitrogen,
Spain). Triglycerides were extracted using isopropanol and quantified
using a colorimetric based commercially available kit (Cromatest,
Spain). All other plasma measurements were conducted by the
Laboratório de Análises Clínicas da Faculdade de Farmácia da
Universidade de Coimbra. To determine insulin sensitivity and glucose
tolerance a glucose tolerance test was performed, by oral gavage of
1.5 g glucose/kg body weight. Blood samples were taken from the tail
vein at several time points after the bolus injection and immediately
flash-frozen for later analysis.
2.4. FAME analysis
Fatty acid composition was determined by gas–liquid chromatogra-
phy after trans-methylation, as previously described (Peixoto et al.,
2004). Before fatty acid derivatization, the exogenous heptadecanoic
acid (C:17) was added to the lipid extract as an internal standard.
Hepatocyte fatty acid methyl esters (FAMEs) were analyzed with a
Trace GC 2000 (Thermo-Finnigan, Thermo Electron Corporation, Austin,
TX) with helium as carrier gas, using an Agilent J &W Scientific (Agilent
Technologies, Inc., Santa Clara, CA) capillary column (SUPELCOWAX 10,
30 m, 0.25 mm id., 0.5 μm film thickness) and a temperature program
as follows: 2 min at 140 °C, 4 °C min−1 to 220 °C and 10 min at the
upper temperature. Injector and flame ionization detector (FID) tem-
peratures were kept at 250 and 270 °C, respectively. Samples of 4 μL
were split-injected and solvent blanks were periodically checked.
FAMEs were identified by comparison with the retention time of
FAME standard (37-Component FAME Mix).
2.5. Preparation of liver mitochondria
Mitochondria were isolated from animals of the three experimental
groups by differential centrifugation, as previously described (Gazotti
et al., 1979), with modifications (Palmeira et al., 1994). The homogeni-
zation buffer contained 250 mM sucrose, 10 mM HEPES (pH 7.4),
0.5 mMEGTAand 0.1% fat-free bovine serumalbumin. EGTA and bovine
serum albumin were omitted from the final washing medium, adjusted
at pH 7.4. Briefly, after homogenization of theminced blood-free hepat-
ic tissue, the homogenatewas centrifuged at 2500 ×g for 10 min at 4 °C.
The resulting supernatant was spun at 10,000 ×g for 10 min at 4 °C to
pellet mitochondria, which were resuspended in more washing medi-
um. This last step was repeated two more times to obtain an ultra-
pure mitochondrial fraction. Protein content was determined by the
biuret method (Gornall et al., 1949) calibrated with bovine serum
albumin.
2.6. Mitochondrial oxygen consumption
Oxygen consumption of isolatedmitochondriawas polarographically
determined with a Clark oxygen electrode (Estabrook, 1967), as previ-
ously described (Rolo et al., 2000). Mitochondria (1 mg) were
suspended under constant magnetic stirring, at 25 °C, in 1.4 mL of stan-
dard respiratory medium (130 mM sucrose, 50 mM KCl, 5 mM MgCl2,
5 mM KH2PO4, 50 μM EDTA, and 5 mM HEPES (pH 7.4) and 2 μM rote-
none). Mitochondria were energized with succinate (5 mM) and State
3 respiration was induced by adding 200 nmol ADP. The oxygen con-
sumption was also measured in the presence of 1 μM carbonylcyanide-
P-trifluoromethoxyphenylhydrazon (FCCP). State 3 and Respiratory
Control Ratio (RCR) were calculated according to Chance and Williams
(1956).
2.7. Membrane potential (ΔΨ) measurements
ΔΨ was estimated using an ion-selective electrode to measure the
distribution of tetraphenylphosphonium (TPP+) according to previous-
ly established methods (Kamo et al., 1979; Palmeira et al., 1994). The
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slope of 59 ± 1, in conformity with the Nernst equation. Reactions
were carried out at 25 °C, in a temperature controlled water-jacketed
chamber with magnetic stirring. Mitochondria (1 mg) were suspended
in 1 mL of standard respiratory medium (as above) supplemented with
3 μMTPP+.Mitochondriawere energizedwith the addition of succinate
(5 mM). A matrix volume of 1.1 μL/mg protein was assumed.2.8. Enzymatic activities
Succinate Dehydrogenase activity was polarographically deter-
mined as previously described (Singer, 1974). The reaction was carried
out at 25 °C in 1.4 mL of standard respiratory medium (as in mitochon-
drial respiration) supplemented with 5 mM succinate, 2 μM rotenone,
0.1 μg Antimycin A, 1 mM KCN and 0.3 mg Triton X-100. After the
addition of freeze–thawed mitochondria (0.25 mg) the reaction was
initiated with 1 mM phenazine methosulfate (PMS).
Cytochrome c Oxidase activitywas polarographically determined, as
previously described (Brautigan et al., 1978). The reaction was carried
out at 25 °C in 1.4 mL of standard respiratory medium supplemented
with 2 μM rotenone, 10 μM oxidized Cytochrome c, 0.3 mg Triton
X-100 and freeze–thawed mitochondria (0.25 mg), after which the re-
action was initiated by adding 5 mM ascorbate plus 0.25 mM tetra
methylphenylene-diamine (TMPD).
ATPase activity was determined spectrophotometrically at 660 nm,
in association with ATP hydrolysis, as previously described (Teodoro
et al., 2008). Briefly, the reaction was carried out at 37 °C, in 2 mL
reaction medium (125 mM sucrose, 65 mM KCl, 2.5 mM MgCl2
and 0.5 mM HEPES, pH 7.4). After the addition of freeze–thawed mito-
chondria (0.25 mg) the reaction was initiated with the addition of
2 mM Mg2+-ATP, in the presence or absence of oligomycin (1 μg/mg
protein). After 10 min, the reaction was stopped by adding 1 mL of
40% trichloroacetic acid and the samples were centrifuged for 5 min at
3000 rpm. 2 mL of ammonium molybdate plus 2 mL H2O was
then added to 1 mL of supernatant. ATPase activity was calculated as
the difference in total absorbance and absorbance in the presence of
oligomycin.2.9. ATP quantification
Adenosine nucleotide extraction was performed as follows. Tissue
samples (20 mg) were pulverized with a mortar and pestle in liquid
N2 and homogenized in ice-cold 25 μL of KOH buffer (KOH 2.5 M,
K2HPO4 1.5 M). Homogenates were vortexed and centrifuged at
14,000 ×g for 2 min, at 4 °C. The supernatants were collected and
dissolved in 100 μL of K2HPO4 1 M. pH was adjusted to 7 and samples
were frozen at −80 °C for posterior use. On assay day, adenosine
nucleotides were quantified with an ATP bioluminescent assay kit
(Sigma-Aldrich) on a Victor3 (PerkinElmer, Waltham, MA) plate reader.2.10. Evaluation of reactive oxygen species (ROS) generation
ROS generation was fluorometrically determined using a
PerkinElmer VICTOR3 plate-reader, with an excitation wavelength of
485 nm and an emission wavelength of 538 nm, respectively corre-
sponding to the excitation and emission wavelengths of 2′,7′-
dichlorodihydrofluorescein diacetate (H2DCFDA) (Zhou et al., 2001).
Isolated mitochondria (1 mg/mL) were suspended in standard respira-
tory medium and loaded with succinate 5 mM and H2DCFDA 50 μM
(prepared in DMSO) for 15 min at 25 °C. 200 μL of the mitochondrial
suspension was loaded into a 96-well plate and the fluorescence was
monitored for 30 min to calculate the rate of ROS formation. The results
were expressed as arbitrary relative fluorescence units (RFUs).2.11. Measurement of the mitochondrial permeability transition
Mitochondrial swellingwas estimated by changes in light scattering,
asmonitored spectrophotometrically at 540 nm (Palmeira andWallace,
1997). Reactionswere carried out at 25 °C. Recordingwas started by the
addition of mitochondria (1 mg) to 2 mL of swellingmedium (200 mM
sucrose, 10 mM Tris–MOPS, 1 mM KH2PO4 and 10 μM EGTA pH 7.4)
supplemented with 3 μM rotenone and 5 mM succinate. After a brief
period for the recording of basal absorbance, different amounts of
Ca2+ were added and the resulting alterations in light scattering were
registered.
2.12. Western blotting analysis
Tissue homogenates were lysed in ice-cold RIPA lysis buffer
supplemented with a cocktail of protease and phosphatase inhibitors
(Sigma-Aldrich). Equal amounts of protein (measured with a
Bicinchoninic Acid Kit, Sigma-Aldrich) were loaded and electrophoresed
on a home-made SDS-polyacrylamide gel and transferred to a poly-
vinylidene difluoride membrane (Bio-Rad Laboratories, Hercules, CA).
Membranes were blocked with 5% blocking solution (Bio-Rad) for 2 h
and incubated in Tris-buffered saline (TBS) supplemented with 1%
Tween-20 (TBS–T) and blocking solution 0.5%, overnight at 4 °C, with
anti-PGC-1α (Cell Signaling Technology, Beverly, MA, 1:100), anti-SirT1
(Cell Signaling Technology, 1:1000), anti-SirT3 (Cell Signaling Technolo-
gy, 1:500), anti-TFAM (Aviva Systems Biology, San Diego, CA, 1:2000),
anti-NRF1 (Aviva Systems Biology, 1:1000), anti-ATP synthase (Aviva
Systems Biology, 1:1000), anti-COX I (MitoSciences, Eugene, OR,
1:1000), anti-COX IV (MitoSciences, 1:10,000) or anti-β-actin (Sigma-
Aldrich, 1:5000) antibody. The following day, membranes were washed
in room temperature TBS–T 3 times for 30 min and incubatedwith a cor-
responding secondary antibody (Invitrogen, Carlsbad, CA). Membranes
were then washed in room temperature TBS–T 3 times for 15 min and
immunodetection was performed with WesternDot 625 goat anti-
rabbit or goat anti-mouse western blot kits (Invitrogen). Membranes
were imaged using a VersaDoc Instrument (Bio-Rad).
2.13. RNA isolation and genetic expression evaluation by qPCR
Flash-frozen liver RNA was extracted with an AxyPrep RNA extrac-
tion kit (Axygen, Union City, CA). Total RNA was quantified by the use
of the Experion Automated Electrophoresis Station (Bio-Rad) and cDNA
was generated from RNA with an iScript cDNA synthesis kit (Bio-Rad),
following manufacturer's recommendations. Semi-quantitative real-
time PCR was conducted with a SYBR Green real-time PCR kit (Bio-
Rad), following manufacturer's recommendations. Utilized primers
were, 5′-3′ (Gene, Forward primer, Reverse primer.): COX II, tgg ctt aca
aga cgc cac at; tgg gcg tct att gtg ctt gt; COX IV, act acc cct tgc ctg atg
tg, act cat tgg tgc cct tgt tc; PDK4, cct ttg gct ggt ttt ggt ta, cac cag tca
tca gcc tca ga; PEPCK, ccc agg agt cac cat cac tt, ttc gta gac aag ggg gac
ac; atg tgt cgc ctt ctt gct ct, atc tac tgc ctg ggg acc tt; SirT1, cca gat cct
caa gcc atg tt, gat cct ttg gat tcc tgc aa; SirT3, gct gcc agc aag gtt ctt
ac, cct ttc cac acc ctg gac ta, TFAM, atc aag act gtg cgt gca tc, aaa gcc
cgg aag gtt ctt ag; and 18S, cgc ggt tct att ttg ttg gt, agt cgg cat cgt tta
tgg tc.
2.14. SirT3 activity
SirT3 activity was measured in mitochondrial extracts using the
SirT3 direct fluorescent screening assay kit (Cayman Chemical Compa-
ny, Ann Arbor, MI). A kit-supplied acetylated, fluorescently labeled
sirtuin-3 peptide substrate is mixed with the freeze–thawedmitochon-
drial preparations isolated before (25 mg) at 37 °C for 45 min. 25 μL of
developer is then added and following 30 min of incubation, the fluo-
rescence intensity was measured on a Victor3 plate reader, with excita-
tion and emission wavelengths of 340 and 440 nm, respectively. It is
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sirtuins, but since in mitochondria only SirT3–5 are present and since
SirT4 is not a deacetylase (Huang et al., 2010) and SirT5 has an extreme-
ly reduced deacetylating activity (Du et al., 2011), it is safe to assume
that SirT3 is accounted for virtually all of the fluorescence.
2.15. Statistical analysis
Data is represented as amean of n ≥ 4 ± SEM, and statistical signif-
icance was determined using the one-way (two-way for the swelling
analysis) ANOVA test with a Bonferroni correction (GraphPad Prism
software, La Jolla, CA). A value of p b 0.05 was considered statistically
significant.
3. Results
3.1. Animal model characterization
In order to demonstrate the effectiveness of the high-fat diet in
terms of body weight gain, the animals were weighted once a week,
with themain results being summarized below. The high fat feeding un-
surprisingly caused the body weight of the animals to increase signifi-
cantly. In fact, just after one month of high fat feeding, the body
weight increase of theHFD groupwas statistically significant. BBR treat-
ment completely reversed the effect of high-fat feeding during
4 months in just one month (Fig. 1A). There were no effects detected
on food consumption in any of the diets by simple evaluation of the
weight of diets placed on the cages (data not shown).
Following total body weight, the total liver weight in HFD was also
significantly elevated; again, BBR prevented this phenotype (Ctl:
12.6 g ± 0.4; HFD: 17.14 g ± 1.3; BBR: 10.86 g ± 0.7 — HFD liver
weight is statistically heavier than Ctl and BBR). As far as blood serumFig. 1. A: Total body weight at the end of the 4 months of study. HFD animals had a massive bo
HFDdiet led to a dramaticweight loss in just onemonth. B: Area under curve for an oral glucose
BBR recovered such capacity. C: Area under curve for the insulin levels after a glucose challenge.
statistically significant difference versus control (p b 0.05); & indicates a statistically significanbiochemical parameters, several alterations were found, induced by
the treatments (Table 1). Of particular relevance, BBR reverted the
high-fat diet effects on fasting and fed glycemic levels, HbA1c, circulat-
ing triglycerides and phospholipids, leptin and insulin levels (Table 1).
The return of all of these metabolic indicators back to control levels
illustrates a positive effect of BBR on reverting the effects of feeding a
high-fat diet.
The evaluation of the data from the oral glucose tolerance test dem-
onstrated that the HFD animals were incapable to rapidly reduce their
circulating glucose levels, at least as fast as the Ctl animals (Fig. 1B).
BBR restored this capacity, which could indicate that BBR recovered
the animals' insulin sensitivity. As such, insulin level quantification
was required. Data from such assay (Fig. 1C) demonstrates that HFD an-
imals were hyperinsulinemic, while BBR was able to recover insulin
sensitivity to the animals.
Moreover, FAME analysis of the spectra of fatty acid methyl esters
demonstrates the same pattern: “bad” (saturated or trans) fats (Stearic,
Elaidic and Linolelaidic acids) are elevated in HFD animals, while “good”
(unsaturated) fats (Oleic, Linolenic and Eicosatrienoic acids) are elevat-
ed in BBR-supplemented animals (Fig. 2).3.2. Effects of high fat feeding and berberine supplementation on liver
mitochondrial function
Since mitochondria are the main site for energy generation in the
eukaryotic cell (as well as being crucial for a panoply of other biological
processes), we evaluated how high fat feeding and BBR supplementa-
tion affected mitochondrial function. Oxidative phosphorylation relies
on the generation of a transmembrane electrochemical potential
(in the form of a protonic gradient) or ΔΨ, associated with molecular
oxygen consumption. These parameters can be directly measured in
isolated mitochondria. No significant variation on the activity of citratedy weight increase, when compared to chow-fed Ctl animals. BBR supplementation to the
tolerance test. HFD feeding led to an incapacity to decrease circulating glucose levels, while
Bars represent average ± SEMof bodyweight or AUC. n = at least 4 animals; * indicates a
t difference versus HFD (p b 0.05).
Table 1
Blood serum biochemical parameters. HFD animals had alterations in several biochemical




130.6 ± 5.48 157.1 ± 9.43a 114.8 ± 4.00b
Fasted
Glycemia (mg/dL)
67.7 ± 2.64 79.08 ± 3.20a 63.14 ± 4.36b
Insulin (pmol/L) 90.25 ± 8.99 159.0 ± 26.76a 67.25 ± 8.37b
HbA1c (%) 3.28 ± 0.06 3.57 ± 0.06a 3.30 ± 0.05b
HDL cholesterol (mg/dL) 39.7 ± 3.87 63.00 ± 5.59a 39.33 ± 4.40b
Non-HDL cholesterol
(mg/dL)
27.4 ± 1.82 36.0 ± 3.94 28.7 ± 4.54
Free fatty acids (mM) 0.46 ± 0.06 0.40 ± 0.07 0.54 ± 0.03
Leptin (pg/mL) 4434 ± 714 20,399 ± 3869a 579 ± 93.1b
Adiponectin (ng/mL) 10,407 ± 1727 19,111 ± 1615a 31,944 ± 3893a,b
Triglycerides (mg/dL) 56.0 ± 6.21 94.9 ± 9.66a 44.3 ± 5.75b
Atherogenic index 1.66 ± 0.05 1.56 ± 0.06 1.72 ± 0.07
Phospholipids (mg/dL) 115.5 ± 7.88 158.5 ± 9.40a 116.8 ± 7.78b
Albumin (mg/dL) 3.30 ± 0.05 3.25 ± 0.05 3.07 ± 0.06a
Creatinine (mg/dL) 0.52 ± 0.01 0.55 ± 0.02 0.52 ± 0.02
Ureic nitrogen (mg/dL) 15.6 ± 1.24 11.9 ± 1.48 15.43 ± 2.77
Uric acid (mg/dL) 1.58 ± 0.05 1.60 ± 0.37 1.12 ± 0.04
Alanine aminotransferase
(U/L)
52.4 ± 1.88 72.0 ± 9.81 66.0 ± 4.57
Aspartate aminotransferase
(U/L)
157.9 ± 8.21 154.0 ± 5.32 157.0 ± 9.32
Alkaline phosphatase (U/L) 147.2 ± 21.25 270.5 ± 26.88a 142.7 ± 34.10b
γ-Glutamyl transferase
(U/L)
1.11 ± 0.26 0.75 ± 0.16 0.50 ± 0.22
Total bilirubin (mg/dL) 0.13 ± 0.02 0.12 ± 0.02 0.15 ± 0.02
Lactate dehydrogenase
(U/L)
1157 ± 158 1460 ± 541 707 ± 84.2
Creatine kinase (U/L) 8756 ± 2635 18,462 ± 7416 6322 ± 1362
Acid phosphatase (U/L) 20.08 ± 1.27 21.77 ± 1.05 16.30 ± 0.93a
a Indicates a statistically significant difference versus control (p b 0.05).
b Indicates a statistically significant difference versus HFD (p b 0.05).
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different experimental groups (data not shown).3.2.1. Mitochondrial membrane potential
Fig. 3A illustrates the membrane potential of isolated liver mito-
chondria from the animals of the different experimental groups, when
energized with succinate.Fig. 2. Fatty acidmethyl ester (FAME) profile of rat hepatocytes obtained from control (Ctl), high
fatty acids and are the means ± SEM of at least 5 independent experiments. * indicates a statis
difference versus HFD (p b 0.05).Comparative to chow controls, high fat feeding led to a significant
decrease in mitochondrial ΔΨ. However, BBR caused the improvement
in mitochondrial coupling, rescuing the high fat effect (Fig. 3A).
ADP-induced depolarizationwas curiously not affected by the high fat
feeding; nonetheless, BBR treatment restored the depolarization potential
(Fig. 3A), suggesting an overall beneficial effect on BBR on mitochondria,
which is not damage-dependent (as, for example, acting as a scavenger).
A negative effect of high fat feeding on repolarization potential was
unveiled, which was again reverted by BBR (Fig. 3A).
Finally, the lag phase (or time necessary to complete a phosphoryla-
tive cycle) was increased due to high fat feeding, illustrating a clear im-
pairment of mitochondrial function. Once again, BBR was sufficient to
revert such effect (Fig. 3A).
3.2.2. Mitochondrial respiration
Oxidative phosphorylation capacity of mitochondria isolated from
control, high fat fed and BBR-exposed animals was investigated by fol-
lowing oxygen consumption upon succinate oxidation. Mitochondrial
respiratory State 3 (consumption of oxygen in the presence of substrate
and ADP)was decreased inmitochondria isolated fromHFD animals, an
effect reversed by BBR (Fig. 3B). Similarly, oxygen consumption in the
presence of FCCP, a well-known respiratory chain uncoupler, was also
decreased in HFD and, once again, this effect was absent when BBR
was supplemented to the high fat fed animals (Fig. 3B).
Surprisingly, no effects of high fat feeding or BBR intake were found
in either State 4 respiration or in the presence of oligomycin, a known
inhibitor of the mitochondrial FO-ATP synthase (Fig. 3B), which leads
to the conclusion that mitochondrial membrane integrity was not af-
fected throughout the experimental groups, nor was the ATP synthase
affected by the high fat diet, causing protonic leakage.
Nevertheless, corresponding to a decrease in State 3 respiration, the
Respiratory Control Ratio (RCR) was decreased in HFD mitochondria.
BBR was once again able to fully recover this effect (Fig. 3B).
The ADP/O ratio, an indicator of oxidative phosphorylation efficien-
cy, was found to be unaltered, independently of the experimental group
(Fig. 3B).
3.3. Mitochondrial enzymatic activities
This data was thus indicative of damage to the components of the
mitochondrial respiratory chain. As such, the evaluation of the activity-fat diet (HFD) and berberine (BBR) groups. Data are expressed as the percentages of total
tically significant difference versus control (p b 0.05); & indicates a statistically significant
Fig. 3.A: Isolated livermitochondriamembrane initial potential, depolarization potential, repolarization potential and lag phase of animals fed a control chowdiet, a high fat diet or a high
fat diet supplemented with BBR. B: State 3 respiration, State 4 respiration, oxygen consumption in the presence of oligomycin, FCCP-stimulated oxygen consumption, Respiratory Control
Ratio (RCR) and ADP/O of succinate-energized liver mitochondria isolated from animals fed a control chow diet, a high fat diet or a high fat diet supplemented with BBR. n = at least 4
animals; * indicates a statistically significant difference versus control (p b 0.05); & indicates a statistically significant difference versus HFD (p b 0.05).
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nase (Complex II) revealed an impairment of this activity as a result of
high fat feeding. This effect was rescued by the supplementation of
BBR (Fig. 4A).
The activity of another element of themitochondrial oxidative phos-
phorylation system, the ATP synthase (Complex V), was also evaluated,
by resource to awell-knownproperty of the complex, the capacity to re-
verse its activitywhen themembrane potential is destroyed, consuming
ATP to eject protons, as described in Section 2.8 and before (TeodoroFig. 4.A: Cytochrome c Oxidase activity, Succinate Dehydrogenase activity and ATPase activity o
chowdiet, a high fat diet or a high fat diet supplementedwith BBR. B: ATP quantification of liver
supplemented with BBR. Bars represent average ± SEM of enzymatic activities or ATP quantific
(p b 0.05); & indicates a statistically significant difference versus HFD (p b 0.05).et al., 2008). Once again, BBR rescued the activity of this mitochondrial
complex (Fig. 4A). Adding to this, ATP quantification demonstrated
that HFD caused a significant decrease in ATP content in HFD animals,
an effect that was rescued by BBR (Fig. 4B).
3.4. Mitochondrial calcium metabolism
Mitochondrial calcium retention capacity is an important compo-
nent of mitochondrial cellular activity, for the mitochondria serve asf themitochondrial ATP synthase of liver mitochondria isolated from animals fed a control
mitochondria isolated from animals fed a control chow diet, a high fat diet or a high fat diet
ation. n = at least 4 animals; * indicates a statistically significant difference versus control
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cofactor. But this capacity is not limitless for, after a certain threshold,
there is induction of the so-calledmitochondrial permeability transition
(mPT), a phenomenon known for the release of high molecular weight
solutes from within the mitochondria, possibly through the formation
of a multi-channel pore. Simply put, the amount of calcium the
mitochondria can accumulate and for how long is an extremely useful
indicator of mitochondrial function and status.
As is visible in Fig. 5A, unstimulatedmitochondria do not swell, inde-
pendently of the diet fed to the animals, as well as mitochondria in the
presence of a high calcium dose and Cyclosporine A. This is an indicatorFig. 5. Mitochondrial permeability transition induction evaluation of liver mitochondria
isolated from animals fed a control chow diet, a high fat diet or a high fat diet
supplemented with BBR. After a small period of time to obtain a basal absorbance level,
2 concentrations of calcium (20 and 40 μM) were added to individual preparations. The
absorbance traces were normalized against a control preparation supplemented with
calcium and Cyclosporine A, a known mPT inhibitor. Traces represent the average ±
SEM of the assays. A: Traces obtained without calcium addition; B: Traces obtained in
the presence of 20 μMof calcium; C: Traces obtained in the presence of 40 μMof calcium.
n = at least 4 animals; * indicates a statistically significant difference of HFD versus Ctl
(p b 0.05); # indicates a statistically significant difference of BBR versus Ctl (p b 0.05); $
indicates a statistically significant difference of BBR versus HFD (p b 0.05).of the integrity of the isolated mitochondria. But, as soon as calcium is
added to the preparation, a clear decrease in absorption is notorious.
The faster the decrease, the worse the mitochondrial calcium retention
capacity. As so, it is perfectly visible that HFDmitochondria are the ones
with theworse calcium retention capacity, being able to retain less than
half of the calcium the mitochondria can control (Fig. 5B and C). BBR
supplementation appears to be able to recover the calcium retention
capacity, especially for a low dose of calcium (20 μM, Fig. 5B). In fact,
it takes on average 19 min to statistically differentiate the curves from
HFD and BBR mitochondria, in the presence of 20 μM of calcium
(Ctl and HFD are different from min 10; Ctl and BBR are different from
min 12). The addition of a higher dose of calcium (40 μM) further dem-
onstrates the same pattern (Fig. 5C). Ctl and BBR are not statistically dif-
ferent, in any point of analysis; however, Ctl and HFD are different from
min 15 onward, while HFD and BBR are only different from min 14 to
min 20, which indicates that this high dose of calcium is almost at the
threshold for these mitochondrial preparations.
3.5. Mitochondrial ROS generation
Mitochondrial ROS generation was also evaluated by resource to the
H2O2-sensitive probe, H2DCFDA, as described in Section 2.10. Despite a
trend for higher ROS generation in high fat-fed animals, no statistical
difference was found between Ctl and HFD, an effect that could be
attributable to a rather high data scattering. Conversely, BBR ROS gener-
ation is statistically lower than HFD (Fig. 6).
3.6. Genetic expression and protein content
The gene expression of some relevant genes that was evaluated by
semi-quantitative real-time PCR, as described in Section 2.13, is re-
sumed in Fig. 7A.
Only the BBR animals' SirT3 levels were found to be elevated when
compared to the HFD animals. No other differences were found, despite
a clear upregulation of PGC-1α induced by BBR, and reversal effects of
BBR in SirT1 and PDK4 genes.
We further assessed if protein levels were altered by the diets.
Surprisingly, we found no alterations caused by any of the diets, for
the proteins tested (Fig. 7B and C).
3.7. SirT3 activity
Since SirT3 is a mitochondrial matrix protein responsible for control-
lingmetabolism, being expressed in situations ofmetabolic improvementFig. 6.Mitochondrial ROS generation evaluation of liver mitochondria isolated from ani-
mals fed a control chow diet, a high fat diet or a high fat diet supplemented with BBR.
After a basal fluorescence measurement, Antimycin A was added to all preparation to
block Complex III of the mitochondrial respiratory chain, to induce maximal ROS genera-
tion. Bars represent average ± SEM of Antimycin A-induced ROS generation. n = at least
4 animals; & indicates a statistically significant difference versus HFD (p b 0.05).
Fig. 7. A: Liver genetic expression of several genes involved in metabolic regulation. Data is presented as number of copies of the gene per copy of 18S. B: Liver quantification of several
proteins involved in metabolic regulation. SirT1, Sirtuin 1; SirT3, Sirtuin 3; COX II, Cytochrome c Oxidase, subunit II; COX IV, Cytochrome c Oxidase, subunit IV; PGC1a, Peroxisome
Proliferator-Activated Receptor γ Coactivator 1 α; TFAM, Mitochondrial Transcription Factor A; PEPCK, Phosphoenolpyruvate Carboxykinase; PDK4, Pyruvate Kinase Dehydrogenase iso-
zyme 4. C: Liver quantification of several proteins involved inmetabolic regulation. Representative images collected during analysis. Bars represent average ± SEM of gene expression or
protein quantification. n = at least 4 animals; * indicates a statistically significant difference versus control (p b 0.05).
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is involved in the effects of BBR supplementation. To analyze this,we eval-
uated SirT3 activity from the previously obtainedmitochondrial prepara-
tions, finding that this deacetylase had a decreased activity in HFD
animals, which was reversed by BBR supplementation (Fig. 8), which is
in accordance with our previous study (Gomes et al., 2012). Since SirT3
is the most capable mitochondrial NAD+-dependent deacetylase (Du
et al., 2011; Huang et al., 2010) it is clear that this results are virtually
dependent on the preparations' SirT3.
4. Discussion
Diabetes and its associated conditions, such as obesity and cardio-
vascular diseases are quickly becoming a leading cause of morbidityFig. 8. SirT3 activity of liver mitochondria isolated from animals fed a control chow diet, a
high fat diet or a high fat diet supplemented with BBR. Bars represent average ± SEM of
SirT3 activity. n = at least 4 animals; * indicates a statistically significant difference versus
control (p b 0.05); & indicates a statistically significant difference versus HFD (p b 0.05).and mortality in the world. Estimates from the International Diabetes
Federation (The Global Burden | International Diabetes Federation,
2013) predict that in the next two decades the number of people
afflicted by diabetes will practically double from the current number,
to about 438 million, which means that almost 8% of the world popula-
tion will be affected. Several works have shown the vital role of glucose
homeostasis to prevent or delay the onset of diabetes morbidity. The
liver assumes a vital role in the maintenance of adequate circulating
glucose levels, by being the main organ for gluconeogenesis and glyco-
gen synthesis (Levine and Haft, 1970). As such, the control of glucose
and lipid metabolism in the liver is an attractive target to counteract
the pernicious effects of diabetes and its associated complications.
BBR is an isoquinoline alkaloid, present in the roots, bark and other
plant parts of several species, as for example, Coptis chinensis and Coptis
japonica, Berberis vulgaris, Berberis thunbergii and Berberis aquifolium,
Hydrastis canadensis, among others (Domitrović et al., 2011). These
plants are known in traditional eastern medicine for centuries, and are
widely used for the treatment of several afflictions, such as intestinal
complications and infections. However, the treatment of diabetic pa-
tients for diarrhea with these plants (and through them, with their
main active compound, BBR) leads to the finding of its hypoglycemic
properties. These effects have been extensively explored and investigated
in several studies,which demonstrated that BBR is capable of not only im-
proving glycemia in vivo and in vitro (Kim et al., 2007; Leng et al., 2004; Lu
et al., 2009; Xia et al., 2011), but also increasing insulin expression, β-cell
regeneration, antioxidant enzyme activity, glucose uptake, while decreas-
ing lipid peroxidation (Wang et al., 2009a; Zhang et al., 2008; Zhou et al.,
2009) and cholesterol and triglyceride synthesis (Brusq et al., 2006). All
these effects appear to be insulin independent, relying instead in an in-
crease in the AMP/ATP ratio, thus increasing AMPK activity (Cheng
et al., 2006; Xia et al., 2011; Zhou et al., 2007). Our previous work has
demonstrated that BBR supplementation causes an increase in the ex-
pression levels of nicotinamide phosphoribosyltransferase (NAMPT)
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As such, despite the above-mentioned reports, not all of BBR effects
appear to bemediated through AMPK (Zhou et al., 2010). These previous
works support our data, for the BBR-treated animals presented an
improved plasma profile (Figs. 1 and 2, Table 1). Of particular interest is
the fact that glycemia, phospholipid and triglyceride levels were reverted
to (if not overcame) control levels. A notice should be made for
adiponectin. As an adipokine, adiponectin is released by adipocytes and
its levels seem to be inversely correlated with adiposity and insulin resis-
tance. However, our data demonstrates a different pattern. BBR treated
animals demonstrate an increase of circulating adiponectin levels,
concomitant with a decrease in body weight and overall regression of
obesity-associated characteristics. But adiponectin levels are higher in
the HFD animals, when compared with the chow controls, both in total
concentration and as an index correlated to body mass (data not
shown). This might seem paradoxical, but a previous work demonstrated
a dynamic pattern of adiponectin levels in both C57/Bl6 and A/J mice
(Bullen et al., 2007), when fed a high-fat diet. Also, an extremely interest-
ingwork byKuda et al. (2009) demonstrated that C57/Bl6mice,when fed
a high fat diet, had a nonstatistical trend towards increased adiponectin
levels, when compared to chow-fed controls. We suspect that a similar
phenomenon is taking place in our study. Also, when comparing two
diets with extremely different fat compositions, the results might not be
as predictable, especially when concerning lipid metabolism-involved
metabolites. To highlight this idea, leptin levels are predictably elevated
in HFD animals, and lowered in BBR. Nevertheless, the massive increase
of circulating adiponectin levels in the BBR-treated animals is a clear
and consensual indicator of decreased obesity.
Our data unsurprisingly demonstrates that feeding a high fat diet is
extremely harmful to liver bioenergetic machinery. Not only did the
HFD mitochondria were less efficient, but also took more time to com-
plete a phosphorylative cycle (Fig. 3). This can be attributed to numer-
ous causes, from increased redox imbalance, to membrane alterations,
unto protein efficiency alterations (Fig. 4). BBR not only reverted these
pernicious effects, but also in some of the evaluated parameters, im-
proved them. As such, it is possible to assume BBR supplementation is
hepatoprotective.
Surprisingly, HFD feeding didn't increase ROS generation, despite
the fact that BBR was able to reduce it (Fig. 6). Also without a clear
positive effect, some works have found that BBR does not have an
insulinotropic effect (Wang et al., 2009a, 2011); in fact, one work re-
ported a reduction of insulin secretion after BBR treatment (Zhou
et al., 2008). Also, the leptin and adiponectin levels are inconstant in
some works, in response to BBR. There is also no consensus in regard
to ROS generation. Our work managed to demonstrate an antioxidant
effect of BBR, as reported before (Wang et al., 2009b). These are some
examples, but these discrepancies might be attributable to different ex-
perimental models used and/or different treatment approaches (Wang
et al., 2009b).
However, the simple fact that mitochondrial function and activity
are completely restored as an effect of BBR is a clear indicator of
improvement of hepatic function. Simply by havingmore efficientmito-
chondria, hepatocytes are capable of handling more nutrients (such as
increased lipids) and thus prevent the harmful effects of their accumu-
lation. By having increasedmitochondrial activity, and by the fact that it
can induce thermogenesis-involved genes (Lee et al., 2006), BBR can
significantly revert and prevent the effects of increased fat intake. As
such, BBR utilization has been shown to cause several alterations in
genetic expression, specifically in genes coding for metabolic key
players. In fact, BBR utilization has been demonstrated to reduce the
expression of gluconeogenic and lipogenic genes, while upregulating
catabolic genes and some selected transcription factors (Liu et al.,
2010; Xia et al., 2011; Zhou and Zhou, 2011). Our results do not demon-
strate any alteration, whether on gene expression or protein quantifica-
tion (for the exception of the expression of SirT3). This might have been
caused by the long time course of the study, where these alterationsmight have occurred long before the animals were sacrificed. Neverthe-
less, the restoration of the activity of SirT3, a mitochondrial deacetylase
might provide an insight into the effects of BBR, for SirT3's activity is re-
lated to an improved metabolic profile (Choudhury et al., 2011;
Hirschey et al., 2011; Kendrick et al., 2011). The activity of SirT3 as a
deacetylase has been demonstrated to be vital for metabolic homeosta-
sis. In fact, the loss of SirT3 has been shown to cause hyperacetylation of
mitochondrial proteins, such as Complex I and II, and enzymes involved
in mitochondrial lipidic β-oxidation (Ahn et al., 2008; Cimen et al.,
2010; Hirschey et al., 2011), with concomitant decrease in their activity.
Furthermore, it has been demonstrated that feeding a high-fat diet
causes a SirT3-knockout similar phenotype, through the inhibition of
PGC-1α's effects on SirT3's expression (Hirschey et al., 2011). Also,
SirT3 has been shown to regulate mitochondrial biogenesis, and its
knockdown reduced the effects of PGC-1α on mitochondrial biogenesis
(Kong et al., 2010). Since we have previously demonstrated that BBR
causes an increase in NAMPT expression, thus leading to an increase
in the NAD+/NADH ratio (Gomes et al., 2012), it is plausible to assume
that the effects of BBR on improvement of hepatic mitochondrial func-
tion are vastly dependent on SirT3's increased activity. Several other
works have demonstrated that SirT3's activity is the key for metabolic
improvement. The sirtuin activator NAD+, generated from its precursor
nicotinamide riboside, protects against fatty diet-related injuries (Cantó
et al., 2012); but SirT3's activation by calorie restriction and use of lipoic
acid provides protection againstmetabolic pathologies, notably through
the improvement of mitochondrial activity (Tauriainen et al., 2011;
Valdecantos et al., 2012). As expected, the removal of SirT3 leads to in-
creased metabolic abnormalities and disease (Fernandez-Marcos et al.,
2012; Hirschey et al., 2011; Kong et al., 2010).
4.1. Conclusions
In conclusion, BBR appears to improve the liver metabolic profile
and, to some extent, the whole organism. Mitochondria appear to
have a central role mediating the effects of this compound, for the im-
provement of its parameters will undoubtedly lead to the altered cellu-
lar mechanisms that culminate in the reversal of many of the crippling
features of constant high fat feeding. Research into development of
BBR-like molecules, with similar or even more powerful activity should
begin in the near future in order to develop even more powerful anti-
obesity compounds and therapies. The work presented in this paper
demonstrates that BBR can be a powerful anti-obesity and anti-
diabetic drug in the near future. By showing how BBR leads to improved
hepatic mitochondrial function possibly via activation of SirT3, this
work further validates BBR (and possible chemically-modified deriva-
tives) as a compound to apply in clinical trials in the next few years.
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